Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
A CB(1)/CB(2) receptor agonist, WIN 55,212-2, exerts its therapeutic effect in a viral autoimmune model of multiple sclerosis by restoring self-tolerance to myelin.
Systematic localization of common disease-associated variation in regulatory DNA.
Distinct genetic and infectious profiles in Japanese neuromyelitis optica patients according to anti-aquaporin 4 antibody status.
AB Science announces successful non futility test for masitinib in progressive forms of multiple sclerosis
Treatment of the chronic progressive form of multiple sclerosis with a combination of cyclophosphamide and prednisone.
Effects of Topiramate on Dysaesthetic Pain in a Patient with Multiple Sclerosis.
Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial.
Simvastatin inhibits interferon-gamma-induced MHC class II up-regulation in cultured astrocytes.
The recurrent Guillain-Barré syndrome: a long-term population-based study.
Diffusion-weighted imaging characteristics of biopsy-proven demyelinating brain lesions.
The role of stress-response systems for the pathogenesis and progression of MS.
Identification of VHY/Dusp15 as a Regulator of Oligodendrocyte Differentiation through a Systematic Genomics Approach.
The socioeconomic consequences of optic neuritis with and without multiple sclerosis: a controlled national study.
The Spectrum of Neuromyelitis Optica (NMO) in Childhood.
Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies.
Evaluation of changes in retinal nerve fiber layer thickness and visual functions in cases of optic neuritis and multiple sclerosis.
The Afferent Visual Pathway: Designing a Structural-Functional Paradigm of Multiple Sclerosis.
TH17 cell differentiation is regulated by the circadian clock.
FTY720 induces apoptosis in B16F10-NEX2 murine melanoma cells, limits metastatic development in vivo, and modulates the immune system.
Comprehension and Data-Sharing Behavior of Direct-To-Consumer Genetic Test Customers.
Orbital Doppler evaluation of blood flow velocities in optic neuritis.
Surveillance and medical therapy following endovascular treatment of chronic cerebrospinal venous insufficiency.
Cerebrospinal Fluid BAFF and APRIL Levels in Neuromyelitis Optica and Multiple Sclerosis Patients During Relapse.
Development of nucleic acid drugs for neurological disorders.
Sexual Behavior, Body Image, and Partnership in Chronic Illness: A Comparison of Huntington's Disease and Multiple Sclerosis.
Pages
« first
‹ previous
…
184
185
186
187
188
189
190
191
192
…
next ›
last »